Search

Research Progress on Immunotherapy for Pancreatic Cancer

Author(s)

Ruoqian Que*

Affiliation(s)

School of Life Sciences, Nantong University, Chongchuan District, Nantong, Jiangsu, China *Corresponding Author

Abstract

This study focuses on immunotherapeutic interventions for pancreatic cancer and aims to critically assess the effectiveness and limitations of existing immunotherapeutic methods by comprehensively reviewing relevant treatment forms and clinical results; pancreatic cancer is aggressive and has high death rates worldwide so it poses a great therapeutic difficulty; immunotherapy has been attracting attention over the past few years because of its therapeutic effect on various cancers thus making it a hopeful new cancer treatment approach consequently more research has been conducted to apply immunotherapeutic means to the treatment of pancreatic cancer; the findings indicate that immunotherapy especially combined strategies has had varying degrees of success in treating pancreatic cancer but still faces major challenges such as the diversity of the tumor microenvironment the suppression of the immune system and drug resistance; future research should focus on improving the tumor microenvironment developing combination therapies personalizing medicine regulating the immune system and finding new drugs in order to enhance the therapeutic effect of immunotherapy and give pancreatic cancer patients a better chance of survival.

Keywords

Pancreatic Cancer; Immunotherapy; Combination Therapy; Prospects of Pancreatic Cancer Immunotherapy; Immune Checkpoint Inhibitors

References

[1] Bray, F., M. Laversanne, H. Sung, et al. "Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries." CA: A Cancer Journal for Clinicians, vol. 74, no. 3, May-Jun. 2024, pp. 229-263. [2] Gobbi, Paolo G., et al. "The Prognostic Role of Time to Diagnosis and Presenting Symptoms in Patients with Pancreatic Cancer." Cancer Epidemiology, vol. 37, no. 2, 2013, pp. 186-190. [3] Ruan, W. B., etc. (2024). Recent Advances in Targeted and Immunotherapeutic Approaches for Pancreatic Cancer Management. Chinese General Practice, 1-12. [4] Cai, L., Wang, X. Q., & Wang, H. Z. (2023). Progress and constraints in immunotherapy for the treatment of pancreatic cancer. Chinese Journal of General Surgery, 30(9), 1030-1036. [5] Topalian, Suzanne L., et al. "Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy." Cancer Cell, vol. 27, no. 4, 2015, pp. 450-461. [6] Brahmer, J. R., S. S. Tykodi, L. Q. Chow, et al. "Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer." N Engl J Med, vol. 366, no. 26, 2012, pp. 2455-2465. [7] Xia, Y., et al. "Title of the Article." Blood Rev, vol. 30, no. 3, 2016, pp. 189-200. [8] Contardi, E., et al. "Title of the Article." Int J Cancer, vol. 117, no. 4, 2005, pp. 538-550. [9] Peggs, K. S., et al. "Title of the Article." J Exp Med, vol. 206, no. 8, 2009, pp. 1717-1725. [10]Pedicord, V. A., et al. "Title of the Article." Proc Natl Acad Sci USA, vol. 109, no. 1, 2010, pp. 266-271. [11] KAMATH, S. D., A. KALYAN, S. KIRCHER, et al. "Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase IB Study." Oncologist, vol. 25, no. 5, 2019, pp. e808-e815. [12] Zhan, X., et al. "Radiotherapy Regulates Tumor Immunity and Combines with PD-1/PD-L1 Inhibitors: From Basic to Clinical." Chinese Journal of Oncology, vol. 31, no. 20, 2024, pp. 1276-1284. [13] Lim, J. S., R. A. Soo, et al. "Title of the Article." TherAdvRespir Dis, 2016, 31 Jul. [14] Shao, N., F. Wan, Y. Zhu, et al. "Conditional Survival in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab." Med Sci Monit, vol. 25, 2019, pp. 6518-6522. [15] Nosaki, K., H. Saka, Y. Hosomi, et al. "Safety and Efficacy of Pembrolizumab Monotherapy in Elderly Patients with PD-L1-Positive Advanced Non-Small-Cell Lung Cancer: Pooled Analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 Studies." Lung Cancer, vol. 135, 2019, pp. 188-195. [16] De Sousa Linhares, A., C. Battin, S. Jutz, et al. "Therapeutic PD-L1 Antibodies Are More Effective Than PD-1 Antibodies in Blocking PD-1/PD-L1 Signaling." Sci Rep, vol. 9, no. 1, 2019, article 11472. [17] Feng, M., G. Xiong, Z. Cao, et al. "PD-1/PD-L1 and Immunotherapy for Pancreatic Cancer." Cancer Lett, vol. 407, 2017, pp. 57-65. [18] Wang, S., F. Yao, X. Lu, et al. "Temozolomide Promotes Immune Escape of GBM Cells via Upregulating PD-L1." Am J Cancer Res, vol. 9, no. 6, 2019, pp. 1161-1171. [19] Xu, D., Yang, F., Xia, B. "Current Status and Prospects of Immunotherapy for Pancreatic Cancer." Chinese Journal of Surgical Oncology, vol. 15, no. 1, 2023, pp. 85-91. [20] Du, H., K. Hirabayashi, S. Ahn, et al. "Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells." Cancer Cell, vol. 35, no. 2, 2019, pp. 221-237. [21]Tu D, Yu J, Cai WK, et al. "Research Progress on CAR-T Immunotherapy for Pancreatic Cancer." Medical Journal of the Chinese People's Liberation Army, vol. 47, no. 4, 2022, pp. 419–426. [22] Beatty, G. L., M. H. O’Hara, S. F. Lacey, et al. "Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial." Gastroenterology, vol. 155, no. 1, 2018, pp. 29-32. [23] Sloan, A. E., R. Dansey, L. Zamorano, et al. "Adoptive Immunotherapy in Patients with Recurrent Malignant Glioma: Preliminary Results of Using Autologous Whole-Tumor Vaccine Plus Granulocyte-Macrophage Colony-Stimulating Factor and Adoptive Transfer of Anti-CD3-Activated Lymphocytes." Neurosurgical Focus, vol. 9, no. 6, 2000, pp. 1-8. [24] Massa, C., C. Guiducci, I. Arioli, et al. "Enhanced Efficacy of Tumor Cell Vaccines Transfected with Secretable Hsp70." Cancer Research, vol. 64, no. 4, 2004, pp. 1502-1508. [25] Liu, K., Wu, H. S. "Current Status and Advances in Immunotherapy for Pancreatic Cancer." Journal of Clinical Surgery, vol. 29, no. 7, 2021, pp. 687-690. [26] WANG, L. J., Y. M. XUE, H. LI, et al. "Wilms'Tumour 1-Associating Protein Inhibits Endothelial Cell Angiogenesis by m6A-Dependent Epigenetic Silencing of Desmoplakin in Brain Arteriovenous Malformation." J Cell Mol Med, vol. 24, no. 9, 2020, pp. 4981-4991. [27] PANNEERDOSS, S., V. K. EEDUNURI, P. YADAV, et al. "Cross-Talk Among Writers, Readers, and Erasers of m6A Regulates Cancer Growth and Progression." Sci Adv, vol. 4, no. 10, 2018, article eaar8263. [28] Sun, C. Y. "Current Status of Immunotherapy for Pancreatic Cancer." World Chinese Journal of Digestology, vol. 29, no. 20, 2021, pp. 1151-1157. [29] Zhao, L. J., Li, L., Zou, Z. Y. "Principle and Clinical Research of Personalized Peptide Vaccine for Malignant Tumors." Modern Oncology, vol. 22, no. 3, 2014, pp. 676-679. [30] Bernhardt, S. L., T. A. Buanes, M. Moller, et al. "Imiquimod a New Adjuvant for Telomerase Peptide Vaccine: A Phase I Trial in Patients with Inoperable Pancreatic Cancer." ASCO Annual Meeting Proceedings, vol. 23, 2005, pp. 9623. [31] Gjertsen, M. K., T. Buanes, A. R. Rosseland, et al. "Intradermal Ras Peptide Vaccination with Granulocyte-Macrophage Colony-Stimulating Factor as Adjuvant: Clinical and Immunological Responses in Patients with Pancreatic Adenocarcinoma." Int J Cancer, vol. 92, 2001, pp. 441-450. [32] Wedén, S., M. Klemp, I. P. Gladhaug, et al. "Long-Term Follow-Up of Patients with Resected Pancreatic Cancer Following Vaccination Against Mutant K-Ras." Int J Cancer, vol. 128, 2011, pp. 1120-1128. [33] Tang, Z. H., W. H. Qiu, S. Wu, et al. "The Immunotherapeutic Effect of Dendritic Cells Vaccine Modified with Interleukin-18 Gene and Tumor Cell Lysate on Mice with Pancreatic Carcinoma." World J Gastroenterol, vol. 8, 2002, pp. 908-912. [34] Kim, D., C. F. Hung, T. C. Wu, et al. "DNA Vaccine with α-Galactosylceramide at Prime Phase Enhances Anti-Tumor Immunity After Boosting with Antigen-Expressing Dendritic Cells." Vaccine, vol. 28, no. 45, 2010, pp. 7297-7305. [35] Shojaei F, Ferrara N. "Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies." Drug Resistance Updates, vol. 11, 2008, pp. 219–30. [36] Liotta LA, Kohn EC. "The microenvironment of the tumour-host interface." Nature, vol. 411, 2001, pp. 375–9. [37] Liu WZ, Hu Y, Zhang C. "Research Progress on the Tumor Microenvironment and Immunotherapy of Pancreatic Cancer." Chinese Journal of Immunology, vol. 34, no. 12, 2018, pp. 1901–1906. [38] Mittal K, Ebos J, Rini B. "Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond." Seminars in Oncology, vol. 41, no. 2, 2014, pp. 235–251. [39] Schmid MC, Varner JA. "Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation." Journal of Oncology, vol. 2010, 2010, p. 201026. [40] Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. "Coordinated regulation of myeloid cells by tumours." Nature Reviews Immunology, vol. 12, 2012, pp. 253–68. [41] Wu, B. J., Hu, Z. Q. "Current Status and Advances in Immunotherapy for Pancreatic Cancer." Journal of Clinical Medicine and Pharmacy, vol. 26, no. 13, 2022, pp. 134-138.